Research project award resulting from the "noncompressible hemorrhage (NCH) control technology "
Ended Awarded Last action
- Contract number
- W81XWH2190002
- Awardee
-
Medical Technology Enterprise Consortium UEI RTGVVL7F6J11
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,221,024
Award facts
- Contract value 100% obligated
- $1,221,023.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Summerville, SC 29486, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$274,237 | |
| Supplemental Agreement for work within scope | $265,811 | |
| Supplemental Agreement for work within scope | $127,260 | |
| Original award | $1,102,190 |
About this award
The Defense Health Agency awarded a $1.22M Other Transaction Order to the Medical Technology Enterprise Consortium (Mtec) on February 1, 2021, for development of a Vasobond non-compressible hemorrhage control technology. The contract is scheduled for completion by June 30, 2024, and is being performed in Summerville, South Carolina. This award represents a focused research and development effort to advance medical technologies that address critical battlefield medicine needs, specifically targeting hemorrhage control solutions that cannot be managed through traditional compression techniques. No set-aside designation was used for this award.
Mtec, a nonprofit medical technology accelerator for the Department of Defense, was selected to lead this innovation initiative, leveraging its established consortium model that partners industry, academia, and government entities to rapidly prototype and field advanced medical solutions. The award falls under Mtec's broader Other Transaction Indefinite Delivery Vehicle agreement with the Defense Health Agency, which provides a streamlined contracting mechanism for multiple medical technology development projects supporting military healthcare modernization and operational readiness priorities. The Vasobond technology development aligns with the Department of Defense's ongoing efforts to improve trauma care capabilities and reduce combat casualty mortality through innovative hemorrhage management solutions.
Quick answers
Who was awarded contract W81XWH2190002?
W81XWH2190002 was awarded to Medical Technology Enterprise Consortium by Defense Health Agency (Department of Defense) on February 1, 2021.
How much is contract W81XWH2190002 worth?
The government has obligated $1,221,024 on W81XWH2190002.
Is contract W81XWH2190002 an order under another contract?
Yes. W81XWH2190002 is an other transaction order under W81XWH1590001, an other transaction IDV.
Was contract W81XWH2190002 competed?
The extent of competition for W81XWH2190002 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award